HYUNDAI BIOLAND Co., Ltd.

The niclosamide based candidate and chemotherapy had an anti-cancer efficacy 67% better than chemotherapy alone. Credit: PeopleImages.com – Yuri A via Shutterstock. Hyundai Bioscience is advancing its niclosamide-based cancer candidate into a Phase I/IIa trial for several hard-to-treat cancers following a successful preclinical study in combination with chemotherapy. The candidate, jointly developed with CNPharm, was investigated in combination with the chemotherapy drug docetaxel. In the preclinical study, animals were implanted with triple-negative breast cancer cells and given the combination therapy, or docetaxel alone. The combination treatment was found to be more effective, with the anti-cancer efficacy 67% better than the docetaxel-treated group. The Phase I/IIa trial will be conducted in Korea for various difficult-to-treat cancers, including triple-negative breast cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and metastatic prostate cancer. The drug project will be carried out by a new subsidiary of Hyundai called ADM Korea, said Hyundai’s CEO Oh Sang-gi in the 22 April announcement. Niclosamide is an antiparasitic drug that Hyundai and CNPharm previously developed for Covid-19 and other viral infections under the name Xafty. In June 2023, Hyundai filed results of a Phase II clinical study (NCT04521296) of Xafty with the Korea Disease Control and Prevention Agency for an emergency use authorisation for Covid-19. Its mechanism involves cellular autophagy, a process where cells identify and eliminate foreign invaders like viruses. The broad-spectrum antiviral action is seen as a promising avenue for treating various viral diseases. The drug has also demonstrated efficacy as a cancer treatment by acting on the metabolic processes of cancer cells. Results from Hyundai and CNPharm’s in vitro preclinical test demonstrated efficacy in cancer treatment through multiple mechanisms. The drug disrupts cancer cell metabolism and blocks signalling pathways in tumour cells, preventing drug resistance and impeding cancer recurrence and metastasis. See Also: Syros Pharmaceuticals gets grant for CDK7 inhibitors for treating cancer and other diseases Eurofins Scientific gets grant for method to detect cancer in human individual using cell-free DNA The progress of niclosamide was long hindered by low bioavailability and a short half-life. Through its drug delivery technology, Hyundai’s formulation claims to have a high enough drug concentration to inhibit the proliferation of cancer cells without being toxic. In May 2022, Hyundai announced plans to submit a fast-track processing request for Xafty to the US Food and Drug Administration (FDA) to treat monkeypox. More recently, the company announced that the drug can be used to treat Dengue virus, with plans to get emergency use authorisation (EUA) in areas where dengue fever is an endemic disease. In the announcement accompanying the preclinical data, Hyundai’s R&D lead Jin Geun-Woo said: “This is the first case that is statistically proven in vivo that the oral niclosamide-based anticancer treatment has a remarkable effect on triple-negative breast cancer, a type of cancer that is challenging to treat.”

On Sunday, October 6, thousands will participate in the iconic fundraising walk for Dana-Farber Cancer Institute to support all forms of cancer research and patient care BOSTON, April 17, 2024 /PRNewswire/ -- The annual Boston Marathon® Jimmy Fund Walk presented by Hyundai will culminate at a new finish line this year – inside the heart of the city, at the Boston Common due to ongoing construction in Copley Square. Just a short walk further down Boylston Street, thousands of walkers will join together as they have for more than 35 years to celebrate their beloved Walk in America's oldest public park. Scheduled for Sunday, October 6, funds raised from the Jimmy Fund Walk support all forms of adult and pediatric patient care and cancer research at the nation's premier cancer center, Dana-Farber Cancer Institute. "We are excited for walkers this year to cross the finish line in the Boston Common," said Suzanne Fountain, vice president of the Jimmy Fund. "The move to the Boston Common, affectionately known as the 'People's Park,' marks a symbolic common finish line—a world without cancer. By gathering in Boston Common, we are honoring Boston's roots as a city for the people, connected by a common cause. We are eager to get out on the course and see all our outstanding walkers and teams come together to defy cancer." One Walk, Four Distances, For All Cancers The Jimmy Fund Walk is the only organized walk permitted on the famed Boston Marathon® course, and participants have the flexibility to choose from four distance options: 5K Walk (from Dana-Farber Cancer Institute's Longwood Medical Campus); 10K Walk (from Newton); Half Marathon Walk (from Wellesley); and Marathon Walk (from Hopkinton). Walkers can participate virtually, as well. Whatever route walkers choose, participants will be supported by hundreds of volunteers and treated to refueling stations with refreshments throughout the course. Poster-sized photographs of patients – Jimmy Fund Walk Heroes –are the heart of the event and displayed along the course as inspiration. All routes will conclude at the Jimmy Fund Walk Finish Line Powered by Schneider Electric at Boston Common, by the corner of Charles and Beacon Street. Finish line activities will include a celebration with food, entertainment, and more. The Jimmy Fund Walk has raised more than $176 million for Dana-Farber Cancer in its 35-year history, raising a record-breaking $9.4 million in 2023. Funds raised from the Jimmy Fund Walk support all forms of adult and pediatric patient care and cancer research at the nation's premier cancer center, Dana-Farber Cancer Institute. The Boston Athletic Association has supported the Jimmy Fund Walk since 1989, and Hyundai has been the presenting sponsor for more than 20 years. To register for the Walk (#JimmyFundWalk) or to support a walker, visit or call (866) 531-9255. Registrants can enter the promo code NEWS for $5 off the registration fee. All registered walkers will receive a bib, medal, and a Jimmy Fund Walk T-shirt. About the Jimmy Fund The Jimmy Fund is comprised of community-based fundraising events and other programs that, solely and directly, benefit Dana-Farber Cancer Institute's lifesaving mission to provide compassionate patient care and groundbreaking cancer research for children and adults. The Jimmy Fund is an official charity of the Boston Red Sox, the Massachusetts Chiefs of Police Association, the Pan-Mass Challenge, and the Variety Children's Charity of New England. Since 1948, the generosity of millions of people has helped the Jimmy Fund save countless lives and reduce the burden of cancer for patients and families worldwide. Follow the Jimmy Fund on Facebook, X, and Instagram: @TheJimmyFund. About Dana-Farber Cancer Institute Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. Dana-Farber's mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School. We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 5 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care. As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials. SOURCE Boston Marathon® Jimmy Fund Walk

Hyundai Hope On Wheels announces a new $26 million commitment to pediatric cancer research in its 26th year With this new funding, Hyundai Hope On Wheels has reached a lifetime giving milestone of a quarter-billion dollars ($250 million) since 1998 Hyundai Hope On Wheels announces newest National Youth Ambassador, Emmy Cole, to join fellow ambassador Raynie Clark NEW YORK, March 27, 2024 /PRNewswire/ -- Hyundai Hope On Wheels®, a 501(c)(3) nonprofit organization established by Hyundai Motor America, will award $26 million in research and support grants this year to medical institutions nationwide. With this commitment, the organization reaches a lifetime giving milestone of a quarter-billion dollars as part of its 26th anniversary. Since 1998, Hyundai Hope On Wheels has become one of the leading pediatric cancer charities in America, funding innovative research with the hope of finding a cure and improving outcomes for children affected by the disease. Continue Reading Hyundai Hope On Wheels National Youth Ambassadors Emmy Cole and Raynie Clark are photographed on March 10, 2024 (Photo/Hyundai) "We are proud to have reached this incredible milestone for Hyundai Hope On Wheels, as it truly speaks to the commitment of Hyundai Motor America and its dealers to the cause of ending childhood cancer," said Kevin Reilly, vice chairman of the Hyundai Hope On Wheels Board of Directors, and president of Alexandria Hyundai. "Over the past 26 years, Hyundai Hope On Wheels has fueled cutting-edge research and partnered with doctors and researchers who are equally as dedicated to saving lives and giving hope to people who need it most. Looking ahead, we are honored to continue this fight until we find a cure." In 2024, Hyundai Hope On Wheels will surpass a lifetime total donation of $250 million in support of more than 1,300 research and programmatic grants to over 175 hospitals and research institutions. Hyundai Hope On Wheels awards three categories of grants to researchers at eligible Children's Oncology Group (COG) member institutions, whose work improves outcomes, treatments, and support for children diagnosed with cancer. Hyundai Hope On Wheels' commitment includes $5 million specifically dedicated to survivorship programs. As the survival rate for young cancer patients increases, so does the need to ensure that they can lead a life of opportunity and well-being. This focus on survivorship will be used to bolster initiatives such as long-term care plans, medical records access, and telehealth support. "Research is the cornerstone of our work and is fundamental to finding a cure for all children with cancer," said Dr. Dan Wechsler, a long-standing member of the Hyundai Hope On Wheels Medical Advisory Committee. "Hyundai Hope On Wheels grants help researchers make new discoveries, develop less invasive treatments, and move us closer towards that goal. The addition of survivorship support greatly complements Hope On Wheels' long-time dedication to advancing research, because as more children survive from this disease, the greater the need will be for protecting their health and enhancing care throughout their life." New National Youth Ambassador Emmy Cole, an 11-year-old from outside Seattle, Washington, was announced as the newest National Youth Ambassador from a nationwide search. Throughout the year, Emmy will travel with her fellow National Youth Ambassador, Raynie Clark, to children's hospitals to share their personal stories of hope and courage and help spread awareness of the fight against pediatric cancer. Raynie was selected as the 2023-2025 National Youth Ambassador, while Emmy will serve as the 2024-2026 ambassador. Learn more about Emmy's and Raynie's inspirational stories on the Hyundai Hope On Wheels website. Later this year, Hyundai Hope On Wheels will visit children's hospitals across the nation to present Hope On Wheels grant awards. These ceremonies will culminate in September, National Childhood Cancer Awareness Month, during which Hyundai Hope On Wheels will bring its partners together in Washington, D.C. to honor its 26th anniversary and share more about its expanding vision for the future. Hyundai Hope On Wheels Hyundai Hope On Wheels® is a 501(c)(3) nonprofit organization that is committed to finding a cure for childhood cancer. Launched in 1998, Hyundai Hope On Wheels provides grants to eligible institutions nationwide that are pursuing critical research aimed at improving treatments and saving lives. Hyundai Hope On Wheels is one of the largest nonprofit funders of pediatric cancer research in the country. Primary funding for Hyundai Hope On Wheels comes from Hyundai Motor America and its more than 830 U.S. dealers. In 2024, Hyundai Hope On Wheels will surpass a lifetime total donation of $250 million in support of more than 1,300 childhood cancer research grants to over 175 hospitals and research institutions. SOURCE Hyundai Hope On Wheels